Pelthos Therapeutics ($PTHS) Insider Trading & Smart Money Activity

Pelthos Therapeutics Inc. · Latest filing Oct 2, 2026

Pelthos Therapeutics Inc. ($PTHS) has 3 insider trades on file. In the last 12 months on the open market, no insider bought and 3 insiders sold ($44.94K), net -$44.94K.

Insider buyers (12 mo)

0

Insider sellers (12 mo)

3

Net insider $ (12 mo)

-$44.94K

Congress trades (12 mo)

0

13F moves on file

0

Analyst ratings on file

0

PTHS insider buying and selling by quarter

Quarter	Insider buys	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0	0 / 0	0 / 0
Q2 2026	0	0	0 / 0	0 / 0
Q3 2026	0	0	0 / 0	0 / 0
Q4 2026	0	3 · $44.94K	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All PTHS insider, congress, 13F and analyst activity

All Insiders

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Oct 2, 2026	Insider	Pauls MatthewDirector	Sell (Open-market sale) 10b5-1	786 sh	$16.51K						—
Oct 2, 2026	Insider	Greenleaf PeterDirector	Sell (Open-market sale) 10b5-1	797 sh	$16.87K						—
Oct 2, 2026	Insider	Friedberg Ezra MDirector	Sell (Open-market sale) 10b5-1	558 sh	$11.56K						—

1W / 1M / 6M = how PTHS moved from the trade or filing date.

Insider trading in PTHS: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
Pauls Matthew	Director	1	-$16.51K		Oct 2, 2026
Greenleaf Peter	Director	1	-$16.87K		Oct 2, 2026
Friedberg Ezra M	Director	1	-$11.56K		Oct 2, 2026

Frequently asked questions

Are PTHS insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 3 insiders made 3 open-market sales worth $44.94K, a net -$44.94K.

What is the latest insider trade in PTHS?

Pauls Matthew, Director filed a sell (open-market sale) of 786 sh worth $16.51K on Oct 2, 2026.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.